Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This study, specifically a food effect study, represents a significant milestone in the development of the drug. The study involved the administration of a single 50mg dose of […]
More Stories
How to Delete a Threads Account? Step-by-Step Guide
Just like everyone, I was curious the first time Threads appeared. It was still being referred to as the Twitter...
Andraya Carter’s Wife, Career, Net Worth & Bre Austin Rumors
Andraya Carter has become a famous figure in sports. You might have spotted her on ESPN, or you can even...
Odds of US–EU Trade Deal Are 50–50 Ahead of Tariff Deadline: Trump
By Austin Alonzo President Donald Trump said there’s a 50–50 chance that the United States will finalize a trade deal...
New Mexico Oil and Gas Lease Sale Nets More Than $58 Million: DOI
By Naveen Athrappully The Bureau of Land Management (BLM) New Mexico State Office has generated over $58.26 million in revenues...
US Imposing 20.56 Percent Anti-Dumping Duties on Canadian Softwood
By The Canadian Press British Columbia lumber organizations are condemning the decision by the U.S. Commerce Department to raise anti-dumping...
California Utility Company Offers Direct Compensation to Victims of Eaton Fire Amid Lawsuits, Investigation
By Kimberly Hayek Southern California Edison (SCE) is offering to directly pay victims of the Eaton Fire, the company said...